Depression DisorderNCT07333027
Lonely in Depression
An observational study of Depression Disorder and Loneliness, run by Friedrich-Alexander-Universität Erlangen-Nürnberg at 2 sites in Germany.
Trial summary
The goal of this prospective study is to better understand the link between loneliness and depression in the inpatient psychiatric treatment of depression. It aims to answer: Do lonely and not lonely persons benefit the same way from inpatient depression treatment? Is loneliness a clinical relevant factor in inpatient… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Depression Disorder, Loneliness
- How many people
- 200 participants
- Where
- 2 sitesGermany
- Study dates
- 5 Feb 2026to Sep 2027
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Individuals who are admitted for inpatient treatment at one of the two psychiatric clinics in Erlangen (university hospital, community hospital), Germany, either electively or as an emergency case, due to depressive symptoms.
Who may be able to join
- primary diagnosis of depression according to ICD-10 (F32 or F33), as diagnosed by a physician or clinical psychologist in conjunction with the M.I.N.I. Mini-International Neuropsychiatric Interview diagnostic tools
- inpatient elective or emergency admission to one of the two psychiatric clinics; - age over 18 years
- sufficient understanding of spoken and written German
- informed voluntary consent
Who cannot join
- a current lack of capacity to provide consent (e.g., pronounced psychotic symptoms, stuporous depressive syndrome, and thought constriction to suicidality)
- previous participation in the study
- pregnancy or breastfeeding
- inpatient stay of less than 7 days, even if the patients initially met the inclusion criteria.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Germany2 sites, 2 recruiting
- Recruiting
Friedrich-Alexander-Universität Erlangen-Nürnberg
Erlangen, Bavaria, 91054
Franziska Sonnauer, Dr. med., 00499131-8534597, einsamkeit-depression.ps@uk-erlangen.de
Franziska Sonnauer, Dr. med.
- Not yet recruiting
Bezirkskliniken Mittelfranken, Clinic for Psychiatry, Addiction, Psychotherapie and Psychosomatic Medicine
Erlangen, Bavaria, 91056
Franca Laura Fries, Dr. med., 004991317535353, Franca.Fries@bezirkskliniken-mfr.de
Maksym Druzenko, 004991317535353, Maksym.Druzenko@bezirkskliniken-mfr.de
About this study
Official title: Effects of Loneliness in the Treatment of Depression
The goal of this prospective study is to better understand the link between loneliness and depression in the inpatient psychiatric treatment of depression. It aims to answer:
Do lonely and not lonely persons benefit the same way from inpatient depression treatment? Is loneliness a clinical relevant factor in inpatient treatment of depression? What are the underlying biopsychosocial mechanisms?
Participants will be asked to do some
- self-report questionnaires
- clinical interview
- biosampling (blood, saliva, stool) at three main measurement timepoints (1. begin of inpatient treatment, 2. day of discharge, 3. three months after discharge).
Read the detailed description
Loneliness and depression are widespread and severely debilitating health conditions. Notably, loneliness and depression are closely intertwined, with individuals suffering from depression being particularly vulnerable to loneliness. However, little is known regarding the clinical significance of loneliness in the treatment of depression and the biopsychosocial mechanisms underlying this association.
To examine the clinical relevance of the interplay between loneliness and depression, a prospective, noninterventional longitudinal design will be adopted. The study will be performed at the University Hospital and the community hospital in Erlangen, Germany. Every patient admitted to the hospital with depressive symptoms is eligible for screening according to the inclusion and exclusion criteria. Three main measurement points (T0, T1, and T2) and brief interim measurements conducted at two-week intervals (t0.1 to t0.X and t1.1-t1.6) will be utilized. After screening and clinical interviews, participants will complete the baseline measurements (T0). Thereafter, each participant will adhere to an individual period corresponding to the duration of that specific patient's inpatient stay at the clinic until the second measurement is obtained (T1). Follow-up will occur three months after T1.
Given that the effect sizes of the interaction between loneliness and depression in a clinical population are currently unknown, the sample size for this study was determined based on considerations of practicability and the population generalizability of the obtained results, as well as statistical plausibility.
To ensure the external validity of the results, it is important that both severely lonely depressive patients and less lonely depressive patients, as well as different disease trajectories and patient characteristics (e.g., age, sex, and number of comorbidities), can be identified. A sample size of approximately 200 participants is expected to ensure sufficient heterogeneity. This sample size is practically feasible due to the fact that, even when considering an inclusion rate of 50% and a dropout rate of 30% for the primary diagnosis of depression at the University Hospital and the community hospital in Erlangen, the recruitment potential clearly exceeds the target number of cases within an estimated period of two years.
Without the knowledge of which measured level of loneliness at baseline represents a strong level of loneliness and which measured level represents a weak level of loneliness in a depressed patient population, a median split of loneliness at baseline will be performed to calculate the statistical significance of the interaction between loneliness and depression in the inpatient and follow-up course (T0, T1, and T2). To detect a significant interaction effect of a mixed analysis of variance (ANOVA), when considering an α error of 0.05, a power of 0.9 (1-β error probability) and a correlation value among repeated measures of 0.5 for the groups defined as highly lonely and slightly lonely groups, the number of cases was calculated by using G*Power Version 3.1.9.7. Assuming a small effect size (f= 0.10), the desired sample size would be determined at n= 214 individuals; moreover, assuming a medium effect size (f= 0.25), the sample size would be n= 36 individuals. This indicates that there is statistical plausibility for detecting interaction effects between loneliness and depression with the target number of cases.
Eligibility screening and clinical diagnostic screening, along with interviews, are conducted by study physicians. Depression is assessed during a clinical interview (MADRS) by the patient's treatment team, which also determines when the patient will be discharged from the hospital. All of the self-report assessments are collected by the patients themselves by using the REDCap online survey application. Biosampling will be exclusively performed among participants recruited at the University Hospital to ensure methodologically consistent and rapid processing. Routine clinical data are primarily extracted from clinical documentation systems and consolidated prior to analysis (similar to other data sources).
Given that the study design does not permit definitive causal conclusions to be determined regarding the direction of effects, the findings are expected to provide valuable insights and relevant implications. In particular, the following insights can be obtained: (1) a report on whether more or less lonely patients receive equal benefits from inpatient multimodal depression treatment; (2) insights into changes in loneliness during and after depression treatment; (3) important findings regarding the shared and nonshared biopsychosocial mechanisms underlying loneliness and depression; and (4) the effects of loneliness and depression with respect to secondary outcomes, including quality of life and suicidality.
- Conditions
- Depression Disorder, Loneliness
- Keywords
- loneliness, depression, prospective, biosampling, clinical
- Medical subject headings
- Depression
What is being measured
The primary outcome is the main question the study is designed to answer.
Depression (symptom severity)
Montgomery-Åsberg Depression Rating Scale (MADRS) (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Loneliness
3 Item UCLA Loneliness Scale (3-Item UCLA) (3 items, each item rated 1-3 points, minimum 3 points, maximum 9 points, higher scores indicate greater loneliness)
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Depression
Patient Health Questionnaire, 9-Item Depression Scale (PHQ-9) (9 Items, each item rated 0-4 points, minimum 0 points, maximum 27 points, higher scores indicate greater severity of depression)
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Loneliness
6-Item short scales for Loneliness, De Jong Gierveld Loneliness Scale (6-Item DJGLS) (6 Items, each item rated 1-3 points, before the total score is calculated, the items are dichotomized, thus resulting in a sum score ranging from 0 to 6, wherein scores of 0-1 indicate no loneliness, 2-4 indicate moderate loneliness, and 5-6 indicate severe loneliness)
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Secondary outcomes (7)
Social Support
Fragebogen zur Sozialen Unterstützung (F-SoZ-U 14) (14 Item shortend form, each item rated 0-4 points, minimum 0 points, maximum 56 points, higher total scores indicating higher levels of perceived social support)
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Inpatient treatment duration
in days
Measured: Baseline/T0 (day 1 of inpatient stay) to T1 (end of inpatient stay, normally 7 up to 50 weeks).
Quality of life in self-report
World Health Organization-Five Well-Being Index (WHO-5) (5 Items, each item rated 0-5 points, minimum 0 points, maximum 25 points, the total score (0-25) is transformed to a scale ranging from 0 to 100, with scores ≤50 indicating diminished well-being and higher scores representing higher well-beeing)
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Social Network measure (newly designed for this study)
As there is no culture and language adapted version of a social network indice available an adapted and German-translated version is used to capture participants' social interaction partners during the prior two weeks. The questionnaire was newly developed, with item content informed by existing validated scales (Cohen Social Network Index (SNI), Lubben Social Network Scale (LSNS), Berkman - Social Network/Integration).
Via the use of a yes/no response format, participants indicated whether they had personal or telephone contact with each of the following: (1) spouse or partner, (2) own children, (3) parents or parent-like figures, (4) other relatives (e.g., siblings, uncles, or aunts), (5) friends, (6) neighbors, (7) colleagues, (8) people known through voluntary activities, (9) in-laws (parents, sons, or daughters-in-law), and (10) members of their social group (e.g., community, congregation, sports, or music clubs).
Higher total scores indicate greater social connectedness.
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
General health status
Short Form 12 Health Survey (SF-12) (12 Items, Items rated 0-1, 1-3 and 1-5 and 1-6 scores represent eight dimensions of physical and mental well-beeing with two composite scores, items are recodet, z-transformed and normed, higher values indicate better health)
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Social Anxiety
Social Phobia Inventory (SPIN) (17 Items, each item rated 0-4 points, minimum 0 points, maximum 68 points, higher scores indicate greater severity of social anxiety, three subscales are available (fear 6 items, avoidance 7 items, physiological distress 4 items))
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Somatic Symptom Burden
13-Item Somatic Symptom Severity Scale of the Patient Health Questionnaire (PHQ-13) (13 Items, each item rated 0-2 points, minimum 0 points, maximum 34 points, higher values indicating more somatic symptoms)
Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start5 Feb 2026
- Primary completionSep 2027 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Depression DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Friedrich-Alexander-Universität Erlangen-Nürnberg
- Sponsor type
- University, hospital or other
- Collaborators
- Bezirkskliniken Mittelfranken, Clinic for Psychiatry, Addiction, Psychotherapie and Psychosomatic Medicine, Am Europakanal, Germany
- Responsible party
- Principal investigator, Franziska Sonnauer, Friedrich-Alexander-Universität Erlangen-Nürnberg
- Investigators
- Franziska Sonnauer, Dr. med., M.Sc., Principal investigator, Department of Psychiatry and Psychotherapy, Friedrich-Alexander Universität Erlangen-Nürnberg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07333027
- Sponsor's protocol ID
- 25-435-B
- Status last verified
- Jun 2026
- First submitted
- 2 Dec 2025
- Last updated
- 15 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: IPD used in the results publication No final desicion has been made as several partners are involved and feasibility and regulatory requirements are still under review.
Publications
Sonnauer F, Fries FL, Druzenko M, Kastner UW, Muhle C, Kornhuber J. Clinical relevance of loneliness in the treatment of depression: study protocol for a naturalistic prospective longitudinal study. Front Psychiatry. 2026 Jul 24;17:1827062. doi: 10.3389/fpsyt.2026.1827062. eCollection 2026.
PubMed 42568550
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Loneliness in the Treatment of Depression
- ClinicalTrials.gov ID
- NCT07333027
- Acronym / sponsor ID
- 25-435-B
- Conditions
- Depression Disorder, Loneliness
- Keywords
- loneliness, depression, prospective, biosampling, clinical
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Friedrich-Alexander-Universität Erlangen-NürnbergUniversity, hospital or other
- Collaborators
- Bezirkskliniken Mittelfranken, Clinic for Psychiatry, Addiction, Psychotherapie and Psychosomatic Medicine, Am Europakanal, Germany
- Study start
- 5 Feb 2026 (actual)
- Primary completion
- Sep 2027 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective study is to better understand the link between loneliness and depression in the inpatient psychiatric treatment of depression. It aims to answer:
Do lonely and not lonely persons benefit the same way from inpatient depression treatment? Is loneliness a clinical relevant factor in inpatient treatment of depression? What are the underlying biopsychosocial mechanisms?
Participants will be asked to do some
- self-report questionnaires
- clinical interview
- biosampling (blood, saliva, stool) at three main measurement timepoints (1. begin of inpatient treatment, 2. day of discharge, 3. three months after discharge).
Detailed description
Loneliness and depression are widespread and severely debilitating health conditions. Notably, loneliness and depression are closely intertwined, with individuals suffering from depression being particularly vulnerable to loneliness. However, little is known regarding the clinical significance of loneliness in the treatment of depression and the biopsychosocial mechanisms underlying this association.
To examine the clinical relevance of the interplay between loneliness and depression, a prospective, noninterventional longitudinal design will be adopted. The study will be performed at the University Hospital and the community hospital in Erlangen, Germany. Every patient admitted to the hospital with depressive symptoms is eligible for screening according to the inclusion and exclusion criteria. Three main measurement points (T0, T1, and T2) and brief interim measurements conducted at two-week intervals (t0.1 to t0.X and t1.1-t1.6) will be utilized. After screening and clinical interviews, participants will complete the baseline measurements (T0). Thereafter, each participant will adhere to an individual period corresponding to the duration of that specific patient's inpatient stay at the clinic until the second measurement is obtained (T1). Follow-up will occur three months after T1.
Given that the effect sizes of the interaction between loneliness and depression in a clinical population are currently unknown, the sample size for this study was determined based on considerations of practicability and the population generalizability of the obtained results, as well as statistical plausibility.
To ensure the external validity of the results, it is important that both severely lonely depressive patients and less lonely depressive patients, as well as different disease trajectories and patient characteristics (e.g., age, sex, and number of comorbidities), can be identified. A sample size of approximately 200 participants is expected to ensure sufficient heterogeneity. This sample size is practically feasible due to the fact that, even when considering an inclusion rate of 50% and a dropout rate of 30% for the primary diagnosis of depression at the University Hospital and the community hospital in Erlangen, the recruitment potential clearly exceeds the target number of cases within an estimated period of two years.
Without the knowledge of which measured level of loneliness at baseline represents a strong level of loneliness and which measured level represents a weak level of loneliness in a depressed patient population, a median split of loneliness at baseline will be performed to calculate the statistical significance of the interaction between loneliness and depression in the inpatient and follow-up course (T0, T1, and T2). To detect a significant interaction effect of a mixed analysis of variance (ANOVA), when considering an α error of 0.05, a power of 0.9 (1-β error probability) and a correlation value among repeated measures of 0.5 for the groups defined as highly lonely and slightly lonely groups, the number of cases was calculated by using G*Power Version 3.1.9.7. Assuming a small effect size (f= 0.10), the desired sample size would be determined at n= 214 individuals; moreover, assuming a medium effect size (f= 0.25), the sample size would be n= 36 individuals. This indicates that there is statistical plausibility for detecting interaction effects between loneliness and depression with the target number of cases.
Eligibility screening and clinical diagnostic screening, along with interviews, are conducted by study physicians. Depression is assessed during a clinical interview (MADRS) by the patient's treatment team, which also determines when the patient will be discharged from the hospital. All of the self-report assessments are collected by the patients themselves by using the REDCap online survey application. Biosampling will be exclusively performed among participants recruited at the University Hospital to ensure methodologically consistent and rapid processing. Routine clinical data are primarily extracted from clinical documentation systems and consolidated prior to analysis (similar to other data sources).
Given that the study design does not permit definitive causal conclusions to be determined regarding the direction of effects, the findings are expected to provide valuable insights and relevant implications. In particular, the following insights can be obtained: (1) a report on whether more or less lonely patients receive equal benefits from inpatient multimodal depression treatment; (2) insights into changes in loneliness during and after depression treatment; (3) important findings regarding the shared and nonshared biopsychosocial mechanisms underlying loneliness and depression; and (4) the effects of loneliness and depression with respect to secondary outcomes, including quality of life and suicidality.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 3 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals who are admitted for inpatient treatment at one of the two psychiatric clinics in Erlangen (university hospital, community hospital), Germany, either electively or as an emergency case, due to depressive symptoms.
Key inclusion criteria (4 listed)
- primary diagnosis of depression according to ICD-10 (F32 or F33), as diagnosed by a physician or clinical psychologist in conjunction with the M.I.N.I. Mini-International Neuropsychiatric Interview diagnostic tools
- inpatient elective or emergency admission to one of the two psychiatric clinics; - age over 18 years
- sufficient understanding of spoken and written German
- informed voluntary consent
Key exclusion criteria (4 listed)
- a current lack of capacity to provide consent (e.g., pronounced psychotic symptoms, stuporous depressive syndrome, and thought constriction to suicidality)
- previous participation in the study
- pregnancy or breastfeeding
- inpatient stay of less than 7 days, even if the patients initially met the inclusion criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Depression (symptom severity)
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Montgomery-Åsberg Depression Rating Scale (MADRS) (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)
Loneliness
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
3 Item UCLA Loneliness Scale (3-Item UCLA) (3 items, each item rated 1-3 points, minimum 3 points, maximum 9 points, higher scores indicate greater loneliness)
Depression
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Patient Health Questionnaire, 9-Item Depression Scale (PHQ-9) (9 Items, each item rated 0-4 points, minimum 0 points, maximum 27 points, higher scores indicate greater severity of depression)
Loneliness
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
6-Item short scales for Loneliness, De Jong Gierveld Loneliness Scale (6-Item DJGLS) (6 Items, each item rated 1-3 points, before the total score is calculated, the items are dichotomized, thus resulting in a sum score ranging from 0 to 6, wherein scores of 0-1 indicate no loneliness, 2-4 indicate moderate loneliness, and 5-6 indicate severe loneliness)
7 secondary outcomes
Social Support
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Inpatient treatment duration
Time frame: Baseline/T0 (day 1 of inpatient stay) to T1 (end of inpatient stay, normally 7 up to 50 weeks).
Quality of life in self-report
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Social Network measure (newly designed for this study)
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
General health status
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Social Anxiety
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Somatic Symptom Burden
Time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2026.
- Derived from this study: PubMed 42568550Sonnauer F, Fries FL, Druzenko M, Kastner UW, Muhle C, Kornhuber J. Clinical relevance of loneliness in the treatment of depression: study protocol for a naturalistic prospective longitudinal study. Front Psychiatry. 2026 Jul 24;17:1827062. doi: 10.3389/fpsyt.2026.1827062. eCollection 2026.
- Individual participant dataSharing planned: Undecided. IPD used in the results publication No final desicion has been made as several partners are involved and feasibility and regulatory requirements are still under review.
Related trials for Depression Disorder
Recruiting
Unified Protocol in Penitentiary Facilities
Depression Disorders, Anxiety
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Not yet recruitingObservational study
Functional Impact of Psychological Symptoms in Patients With Superior Semicircular Canal Dehiscence Syndrome (SSCD): a National Cross-sectional Study
Superior Semicircular Canal Dehiscence
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Recruiting
Cultural Adaptation of an Online Parenting Intervention to Reduce the Risk of Depression and Anxiety in Adolescents
Risk of Depression and Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Franziska Sonnauer, Dr. med., M.Sc. principal investigator
Department of Psychiatry and Psychotherapy, Friedrich-Alexander Universität Erlangen-Nürnberg
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Depression Disorder and Loneliness, run by Friedrich-Alexander-Universität Erlangen-Nürnberg at 2 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Franziska Sonnauer, Dr. med., M.Sc. (00499131-8534597, franziska.sonnauer@uk-erlangen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Depression (symptom severity) (time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07333027, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.